IHS Chemical Week

EnviroTech :: Regulatory

FDA Criticized for Negligence in Baxter Heparin Case

10:08 AM MST | March 3, 2008 | Deepti Ramesh

The U.S. FDA has been heavily criticized by Congress for not inspecting a plant in China that manufactures the active pharmaceutical ingredient (API) for heparin, a blood-thinning drug made by Baxter International (Deerfield, IL). Heparin has caused four deaths and had other harmful effects on a growing number of patients in the U.S. FDA confused the identity of the company that operates the Chinese API plant with that of another company with a similar name, when the API manufacturer applied for approval of its facility, reports say. The other company had been...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa